IRIS PubliCatt

Richeldi, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.125
EU - Europa 3.412
AS - Asia 1.645
AF - Africa 66
SA - Sud America 35
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.323
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.050
IT - Italia 965
SE - Svezia 813
SG - Singapore 518
CN - Cina 485
PL - Polonia 385
IE - Irlanda 304
ID - Indonesia 213
DE - Germania 186
GB - Regno Unito 179
FR - Francia 167
RU - Federazione Russa 145
IN - India 105
CA - Canada 56
BE - Belgio 50
FI - Finlandia 44
HK - Hong Kong 42
IR - Iran 38
UA - Ucraina 38
JP - Giappone 37
VN - Vietnam 34
KR - Corea 26
NL - Olanda 26
AU - Australia 25
CH - Svizzera 25
SA - Arabia Saudita 24
CI - Costa d'Avorio 22
TR - Turchia 20
CZ - Repubblica Ceca 17
PH - Filippine 14
EG - Egitto 13
PK - Pakistan 13
BR - Brasile 12
CO - Colombia 12
MX - Messico 11
MY - Malesia 11
RO - Romania 11
TW - Taiwan 11
AT - Austria 10
AE - Emirati Arabi Uniti 8
EU - Europa 8
PT - Portogallo 8
ES - Italia 7
GR - Grecia 7
KZ - Kazakistan 7
LT - Lituania 7
BD - Bangladesh 6
NZ - Nuova Zelanda 6
TN - Tunisia 6
BZ - Belize 5
DK - Danimarca 5
IL - Israele 5
NG - Nigeria 5
SD - Sudan 5
ZA - Sudafrica 5
AR - Argentina 4
IQ - Iraq 4
MA - Marocco 4
MD - Moldavia 4
NP - Nepal 4
PE - Perù 4
TH - Thailandia 4
JO - Giordania 3
NO - Norvegia 3
BT - Bhutan 2
CM - Camerun 2
EC - Ecuador 2
HR - Croazia 2
HU - Ungheria 2
KE - Kenya 2
LK - Sri Lanka 2
MG - Madagascar 2
MO - Macao, regione amministrativa speciale della Cina 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BH - Bahrain 1
CL - Cile 1
EE - Estonia 1
GE - Georgia 1
KW - Kuwait 1
ME - Montenegro 1
MM - Myanmar 1
PA - Panama 1
PR - Porto Rico 1
TT - Trinidad e Tobago 1
Totale 9.323
Salva come PNG Salva come JPEG
Città #
Chandler 665
Singapore 400
Warsaw 377
Ashburn 375
Fairfield 330
Dublin 303
Rome 223
Jakarta 210
Milan 189
Wilmington 189
Beijing 184
Woodbridge 156
Princeton 147
San Mateo 136
Houston 132
Seattle 131
Boston 122
Moscow 107
Ann Arbor 104
New York 97
Chicago 95
Cambridge 94
Boardman 44
Los Angeles 42
Jacksonville 41
Brussels 40
London 37
Bremen 35
Marseille 35
Augusta 30
Helsinki 30
Dearborn 28
Redwood City 28
Munich 27
Dong Ket 26
Kish 25
Nanjing 25
Cattolica 23
Washington 23
Abidjan 22
Trieste 21
Hong Kong 20
Norwalk 19
Pune 19
Casalecchio di Reno 18
Frankfurt am Main 17
Kunming 17
San Diego 17
Brno 15
Tokyo 15
Lappeenranta 14
Santa Clara 14
Toronto 14
Dammam 12
Hangzhou 12
Nanchang 12
Shanghai 12
Zurich 12
Andover 11
Busto Arsizio 11
Chiswick 11
Columbus 11
Oggiono 11
Bern 10
Changsha 10
Leawood 10
Central 9
Fremont 9
Millbury 9
Naples 9
Paris 9
Springfield 9
Turin 9
Amsterdam 8
Bologna 8
Guangzhou 8
Monterrey 8
Monza 8
Mumbai 8
Ottawa 8
Redmond 8
Sydney 8
Taipei 8
Al Qatif 7
Boydton 7
Cairo 7
Chita 7
Florence 7
Tianjin 7
Bergamo 6
Hyderabad 6
Nuremberg 6
Palermo 6
Seoul 6
Shenyang 6
Thessaloniki 6
Vicenza 6
Zhengzhou 6
Beauharnois 5
Belize City 5
Totale 5.941
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 431
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. 367
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage 164
Subclinical interstitial lung abnormalities: Lumping and splitting revisited 159
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 147
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials 146
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis 141
Idiopathic Pulmonary Fibrosis: State of the Art for 2023 126
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 124
Assessment of neurological manifestations in hospitalized patients with COVID-19 116
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 108
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 105
Reply to Moodley and to Ravaglia et al 104
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 99
A real-time integrated framework to support clinical decision making for covid-19 patients 97
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials 93
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis 93
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality? 89
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study 87
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 86
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 82
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 79
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 77
Sarilumab use in severe SARS-CoV-2 pneumonia 77
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 76
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends 73
Residual respiratory impairment after COVID-19 pneumonia 71
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society 70
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 69
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 68
COVID-19 and interstitial lung disease: Keep them separate 68
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia 68
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 68
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue 67
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis 67
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study 65
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 65
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient with Crohn's Disease 65
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 64
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: Preliminary results 63
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) 60
Idiopathic pulmonary fibrosis 60
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? 60
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study 60
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry 59
Treatment strategies for asthma: Reshaping the concept of asthma management 58
Severe asthma: One disease and multiple definitions 58
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 57
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper 57
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? 56
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't 56
Current and Future Idiopathic Pulmonary Fibrosis Therapy 55
Antibody-based therapies for idiopathic pulmonary fibrosis 55
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings 55
New frontiers in ultrasonography of the mediastinum: Pediatric EBUS-TBNA 54
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations 54
Residual respiratory impairment after COVID-19 pneumonia 53
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis 53
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 53
Statin therapy and lung disorders 52
Determinants and Evolution of Obstructive Sleep Apnea Syndrome After Myocardial Infarction 52
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study 52
Vaccines and Myocardial Injury in Patients Hospitalized for COVID-19 Infection: the CardioCOVID-Gemelli Study 51
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study 51
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 51
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study 51
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective 51
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach 50
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy 50
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 50
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial 49
The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: Surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory 49
Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management 49
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis 48
Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis 47
Reply to: Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj 47
Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis 46
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease 46
Current Diagnosis and Management of Hypersensitivity Pneumonitis 45
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data 45
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? 45
Do randomized clinical trials always provide certain results? 44
Antibody-based therapies for idiopathic pulmonary fibrosis 43
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis 43
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey 43
Malnutrition in COVID-19 survivors: prevalence and risk factors 42
Post-COVID lung fibrosis: The tsunami that will follow the earthquake 41
Contemporary Concise Review 2018: Interstitial lung disease 40
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 40
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions 40
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis 40
The impact of fixed triple therapy with beclometasone/formoterol/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease (COPD) in an italian context of real life: The TRITRIAL study protocol 40
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement 40
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) 39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 39
Advances with pharmacotherapy for the treatment of interstitial lung disease 39
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management 38
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants 37
Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: What an Indian female patient tells us 37
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis 37
Totale 7.196
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.293
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.293
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020588 0 0 0 0 14 19 25 5 152 113 194 66
2020/20211.449 52 112 117 99 137 116 256 199 88 133 68 72
2021/20221.487 139 75 29 154 55 47 30 237 61 64 335 261
2022/20232.868 310 294 269 420 269 351 131 175 306 145 124 74
2023/20241.991 68 430 90 96 99 203 132 72 88 142 228 343
2024/20251.043 119 97 355 204 268 0 0 0 0 0 0 0
Totale 9.628